U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H10N2O
Molecular Weight 174.1992
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDARAVONE

SMILES

CC1=NN(C(=O)C1)C2=CC=CC=C2

InChI

InChIKey=QELUYTUMUWHWMC-UHFFFAOYSA-N
InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3

HIDE SMILES / InChI
Molecular Formula C10H10N2O
Molecular Weight 174.1992
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Edaravone is a free radical scavenger developed for the treatment of amyotrophic lateral sclerosis.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Edaravone crossed BBB in rats.

Originator

Approval Year

2017
422
Targets

Targets

Primary TargetPharmacologyConditionPotency
CHEMBL1689064: Hydroxyl Radical
1
Target ID: CHEMBL1689064: Hydroxyl Radical
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
RADICUT

Approved Use

Improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke; Inhibition on progression of functional disorder in patients with amyotrophic lateral sclerosis (ALS).

Launch Date

2010
Primary
Approved
8429
RADICUT

Approved Use

Improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke; Inhibition on progression of functional disorder in patients with amyotrophic lateral sclerosis (ALS).

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.48 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2030.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2354 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1049.3 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.24 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5576.72 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5981.91 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1373.5 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.52 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.83 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.04 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.86 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
unhealthy, 58.8 years (range: 29 - 75 years)
n = 184
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Population Size: 184
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
Disc. AE: Respiratory disorder, Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Respiratory disorder (0.5%)
Respiratory failure (1.1%)
Toxic skin eruption (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
AEs

AEs

AESignificanceDosePopulation
Respiratory disorder 0.5%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
unhealthy, 58.8 years (range: 29 - 75 years)
n = 184
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Population Size: 184
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
Toxic skin eruption 0.5%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
unhealthy, 58.8 years (range: 29 - 75 years)
n = 184
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Population Size: 184
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
Respiratory failure 1.1%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
unhealthy, 58.8 years (range: 29 - 75 years)
n = 184
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Population Size: 184
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Page: p. 77
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

inducer
781
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C8
911

CYP2C19
1478

UGT1A1
204

UGT2B7
146

P-gp
1461

BCRP
699

OATP1B1
788

OATP1B3
706

OAT1
599

OAT3
642

OCT2
647
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
OAT1
603
 no
OATP1B1
803
 no
OATP1B3
715
 no
OCT2
648
 no
P-gp
1650
 no
UGT1A1
254
 no
UGT2B7
157
 no
BCRP
773
 yes [IC50 121 uM]
OAT1
603
 yes [IC50 13.6 uM]
edaravone sulfate
1
OAT3
644
 yes [IC50 2.74 uM]
edaravone sulfate
1
OAT3
644
 yes [IC50 72.3 uM]
CYP2C9
1819
 yes [IC50 84.5 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31530
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31530
ChemicalBook
CB02130134
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02130134
ChemicalBook
CB1287462
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1287462
MolPort
MolPort-000-182-197
https://www.molport.com/shop/molecule-link/MolPort-000-182-197
Selleck Chemicals
Edaravone
http://www.selleckchem.com/products/Edaravone.html
ZINC
ZINC000018203737
http://zinc15.docking.org/substances/ZINC000018203737
eMolecules
529123
https://www.emolecules.com/cgi-bin/more?vid=529123
PubMed

PubMed

TitleDatePubMed
Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats.
2002 Sep 13
A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury.
2003 Aug
Normalization by edaravone, a free radical scavenger, of irradiation-reduced endothelial nitric oxide synthase expression.
2003 Aug 22
Clinical usefulness of edaravone for acute liver injury.
2003 Jul
A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo.
2003 Jun
Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.
2003 Mar 7
Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin.
2003 Oct
Edaravone, a newly developed radical scavenger, protects against ischemia-reperfusion injury of the small intestine in rats.
2004 Jan
Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney.
2004 May
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
2005 Feb 1
Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats.
2005 Jan
MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischemia-reperfusion injury in rats.
2005 Jul
A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation.
2005 Jul 27
Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase.
2005 Mar
The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy.
2005 May
Effect of a novel free radical scavenger, edaravone, on puromycin aminonucleoside induced nephrosis in rats.
2005 Oct
A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia.
2006 Apr
Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum.
2006 Aug 7
Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage.
2006 Jun
An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic beta-adrenergic stimulation rat model.
2006 May 15
Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance.
2007 Dec
Amelioration of hepatic ischemia/reperfusion injury in the remnant liver after partial hepatectomy in rats.
2007 Dec
Edaravone reduces ischemia-reperfusion injury mediators in rat liver.
2007 Jan
Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats.
2007 Oct
Edaravone inhibits the induction of iNOS gene expression at transcriptional and posttranscriptional steps in murine macrophages.
2008 Dec
Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism.
2008 Jul
Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes.
2008 Mar
The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice.
2008 Mar 31
Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway.
2008 Sep
[Effects of edaravone on the expression of interleukin-1beta, nuclear factor-kappaB and neuron apoptosis in juvenile rat hippocampus after status convulsion].
2009 Aug
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
2009 Feb
Expression of syndecan-2 in the amoeboid microglial cells and its involvement in inflammation in the hypoxic developing brain.
2009 Feb
Expression of angiotensin II and its receptors in the normal and hypoxic amoeboid microglial cells and murine BV-2 cells.
2009 Feb 18
Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus.
2009 Jan
Protective effect of edaravone against tobramycin-induced ototoxicity.
2009 Jan
Reactive oxygen species modulate growth of cerebral aneurysms: a study using the free radical scavenger edaravone and p47phox(-/-) mice.
2009 Jul
[Effects of edaravone on IRE1 mRNA expression and neuronal apoptosis in the hippocampus of rats with status convulsivus].
2009 Jun
Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells.
2009 Mar
Acute urinary retention and subsequent catheterization cause lipid peroxidation and oxidative DNA damage in the bladder: preventive effect of edaravone, a free-radical scavenger.
2009 Sep
Protective effect of edaravone against PrP106-126-induced PC12 cell death.
2010 Jul-Aug
Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation.
2010 Mar
Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis.
2010 Mar
Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury.
2010 Mar 25
[Effects of edaravone on the expression of GRP78, Caspase-12, and neuron apoptosis in juvenile rat hippocampus after status convulsive].
2011 Jan
Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat?
2011 Jan
Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia.
2014 Jul
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice.
2014 Oct
A novel pyrazolone-based derivative induces apoptosis in human esophageal cells via reactive oxygen species (ROS) generation and caspase-dependent mitochondria-mediated pathway.
2015 Apr 25
Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
2015 Aug
Ginsenoside Rd attenuates Aβ25-35-induced oxidative stress and apoptosis in primary cultured hippocampal neurons.
2015 Sep 5
Patents

Patents

04207317
1
JP2004307364A
1
JP2005029573A
1
JP2011062529A
1
JPH03215426A
1

Sample Use Guides

In Vivo Use Guide
30 mg of edaravone diluted with an appropriate volume of physiological saline, intravenously over 30 minutes twice a day in the morning and the evening (stroke); 60 mg of edaravone diluted with an appropriate volume of physiological saline, intravenously over 60 minutes once a day (amyotrophic lateral sclerosis).
Route of Administration: Intravenous
In Vitro Use Guide
1 uM or more of edaravone inhibited cultured vascular endothelial cell injury in vitro caused by 15-HPETE (hydroperoxyeicosatetraenoic acid).
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:32:23 GMT 2023
Edited
by admin
on Sat Dec 16 19:32:23 GMT 2023
Record UNII
S798V6YJRP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EDARAVONE
HSDB   INN   JAN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
3H-PYRAZOL-3-ONE, 2,4-DIHYDRO-5-METHYL-2-PHENYL-
Systematic Name English
COLOREX PMP
Brand Name English
NORPHENAZONE [MI]
Common Name English
NSC-12
Code English
NSC-2629
Code English
C.I. DEVELOPER 1
Common Name English
NORPHENAZONE
MI  
Common Name English
DEVELOPER Z
Common Name English
RADICUT
Brand Name English
EDARAVONE [USAN]
Common Name English
EDARAVONE [HSDB]
Common Name English
MCI-186
Code English
1-PHENYL-3-METHYL-5-PYRAZOLONE
Systematic Name English
EDARAVONE [ORANGE BOOK]
Common Name English
RADICAVA
Brand Name English
NSC-26139
Code English
JAROCOL PMP
Brand Name English
3-Methyl-1-phenyl-2-pyrazolin-5-one
Systematic Name English
PHENAZONE IMPURITY A [EP IMPURITY]
Common Name English
Edaravone [WHO-DD]
Common Name English
PHENYL METHYL PYRAZOLONE
INCI  
INCI  
Official Name English
ANTIPYRINE RELATED COMPOUND A [USP-RS]
Common Name English
EDARAVONE [MART.]
Common Name English
EDARAVONE [JAN]
Common Name English
PHENYLMETHYLPYRAZOLONE
Systematic Name English
PHENYL METHYL PYRAZOLONE [INCI]
Common Name English
ANTIPYRINE RELATED COMPOUND A [USP IMPURITY]
Common Name English
edaravone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
FDA ORPHAN DRUG 847021
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
WHO-ATC N07XX14
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
FDA ORPHAN DRUG 478215
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
FDA ORPHAN DRUG 754420
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
EU-Orphan Drug EU/3/15/1510
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
FDA ORPHAN DRUG 465514
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
Code System Code Type Description
JAPANESE REVIEW
RADICUT
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY APPROVED JUNE 2015
DRUG BANK
DB12243
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
RXCUI
1921877
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
CHEBI
31530
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
NSC
2629
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
NSC
12
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
SMS_ID
100000088126
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
CAS
89-25-8
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
MESH
C005435
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
DAILYMED
S798V6YJRP
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
ChEMBL
CHEMBL290916
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
PUBCHEM
4021
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
NSC
26139
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
CAS
942-32-5
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
ALTERNATIVE
HSDB
4102
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
WIKIPEDIA
EDARAVONE
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
ECHA (EC/EINECS)
201-891-0
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
CAS
19735-89-8
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
ALTERNATIVE
INN
7362
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
DRUG CENTRAL
4156
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
EVMPD
SUB06453MIG
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
MERCK INDEX
m8072
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1040016
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
ECHA (EC/EINECS)
213-390-4
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
ALTERNATIVE
NCI_THESAURUS
C74323
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
EPA CompTox
DTXSID9021130
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
FDA UNII
S798V6YJRP
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
USAN
DE-18
Created by admin on Sat Dec 16 19:32:27 GMT 2023 , Edited by admin on Sat Dec 16 19:32:27 GMT 2023
PRIMARY
Related Record Type Details
OAT-3
TRANSPORTER -> SUBSTRATE
OAT-1
TRANSPORTER -> SUBSTRATE
WEAK
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A6
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
OAT-3
TRANSPORTER -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A4
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B4
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B15
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INDUCER
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B17
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A9
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A10
METABOLIC ENZYME -> SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A7
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A8
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
Related Record Type Details
Structure of EDARAVONE SULFATE
METABOLITE INACTIVE -> PARENT
Structure of ANTIPYRINE
PARENT -> METABOLITE
Structure of EDARAVONE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Related Record Type Details
Structure of ANTIPYRINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ANTIPYRINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of EDARAVONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966